RPUSD1

Summary

RPUSD1 (RNA pseudouridine synthase domain containing 1, HGNC:14173) is a protein-coding gene on chromosome 16p13.3, encoding RNA pseudouridylate synthase domain-containing protein 1 (Q9UJJ7).

Predicted to enable pseudouridine synthase activity. Predicted to be involved in enzyme-directed rRNA pseudouridine synthesis.

Source: NCBI Gene 113000 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 102 total
• MANE Select transcript: NM_058192

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14173
Approved symbol	RPUSD1
Name	RNA pseudouridine synthase domain containing 1
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Aliases	RLUCL, MGC19600
Ensembl gene	ENSG00000007376
Ensembl biotype	protein_coding
Entrez	113000

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 12 protein_coding, 2 nonsense_mediated_decay

ENST00000007264, ENST00000561734, ENST00000562070, ENST00000563560, ENST00000565377, ENST00000565503, ENST00000565809, ENST00000567114, ENST00000567283, ENST00000569601, ENST00000918138, ENST00000918139, ENST00000947984, ENST00000947985

RefSeq mRNA: 11 — MANE Select: NM_058192 NM_001324086, NM_001324410, NM_001324411, NM_001324412, NM_001324413, NM_001324414, NM_001324415, NM_001369658, NM_001369659, NM_001369660, NM_058192

CCDS: CCDS10426, CCDS81923, CCDS81924

Canonical transcript exons

ENST00000007264 — 6 exons

Exon	Start	End
ENSE00001062022	784974	786377
ENSE00001118601	787556	787744
ENSE00002589006	788256	788381
ENSE00003532997	787354	787477
ENSE00003611069	786827	786928
ENSE00003622015	787077	787179

Expression profiles

Bgee: expression breadth ubiquitous, 205 present calls, max score 90.49.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.1990 / max 83.1444, expressed in 1799 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
155785	16.1990	1799

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	90.49	silver quality
granulocyte	CL:0000094	88.93	gold quality
mucosa of transverse colon	UBERON:0004991	88.62	gold quality
ileal mucosa	UBERON:0000331	87.22	silver quality
right frontal lobe	UBERON:0002810	86.95	gold quality
upper arm skin	UBERON:0004263	86.91	gold quality
tibialis anterior	UBERON:0001385	86.00	silver quality
lower esophagus mucosa	UBERON:0035834	85.75	gold quality
prefrontal cortex	UBERON:0000451	85.70	gold quality
anterior cingulate cortex	UBERON:0009835	85.58	gold quality
monocyte	CL:0000576	85.36	gold quality
Brodmann (1909) area 9	UBERON:0013540	85.30	gold quality
leukocyte	CL:0000738	85.26	gold quality
body of stomach	UBERON:0001161	84.61	gold quality
right hemisphere of cerebellum	UBERON:0014890	84.45	gold quality
apex of heart	UBERON:0002098	84.40	gold quality
spleen	UBERON:0002106	84.19	gold quality
metanephros cortex	UBERON:0010533	83.71	gold quality
skin of leg	UBERON:0001511	83.44	gold quality
frontal cortex	UBERON:0001870	83.34	gold quality
neocortex	UBERON:0001950	83.31	gold quality
esophagus mucosa	UBERON:0002469	83.28	gold quality
transverse colon	UBERON:0001157	83.20	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	83.16	gold quality
cerebellar hemisphere	UBERON:0002245	82.96	gold quality
putamen	UBERON:0001874	82.89	gold quality
cerebellar cortex	UBERON:0002129	82.86	gold quality
skin of abdomen	UBERON:0001416	82.23	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.22	gold quality
blood	UBERON:0000178	82.19	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

23 targeting RPUSD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-3619-5P	99.00	68.87	2308
HSA-MIR-214-3P	98.71	68.12	2128
HSA-MIR-761	98.71	68.07	2051
HSA-MIR-423-5P	98.69	67.48	1522
HSA-MIR-3184-5P	98.56	67.13	1491
HSA-MIR-6827-5P	98.46	64.88	1256
HSA-MIR-5008-5P	98.42	65.87	1019
HSA-MIR-665	97.60	65.64	1781
HSA-MIR-505-5P	97.01	65.54	778
HSA-MIR-3907	96.76	65.04	662
HSA-MIR-2861	95.24	65.47	1056
HSA-MIR-6786-3P	93.73	60.70	52

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rpusd1	ENSDARG00000060192
mus_musculus	Rpusd1	ENSMUSG00000041199
rattus_norvegicus	Rpusd1	ENSRNOG00000023639

Paralogs (3): RPUSD3 (ENSG00000156990), RPUSD4 (ENSG00000165526), RPUSD2 (ENSG00000166133)

Protein

Protein identifiers

RNA pseudouridylate synthase domain-containing protein 1 — Q9UJJ7 (reviewed: Q9UJJ7)

Alternative names: Ribosomal large subunit pseudouridine synthase C-like protein

All UniProt accessions (9): Q9UJJ7, H3BMZ6, H3BQN8, H3BRG3, H3BS55, H3BSG4, H3BU91, H3BUN6, H3BVD0

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the pseudouridine synthase RluA family.

RefSeq proteins (11): NP_001311015, NP_001311339, NP_001311340, NP_001311341, NP_001311342, NP_001311343, NP_001311344, NP_001356587, NP_001356588, NP_001356589, NP_478072* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006145	PsdUridine_synth_RsuA/RluA	Domain
IPR020103	PsdUridine_synth_cat_dom_sf	Homologous_superfamily
IPR050188	RluA_PseudoU_synthase	Family

Pfam: PF00849

UniProt features (29 total): strand 15, helix 4, turn 3, sequence variant 2, chain 1, region of interest 1, compositionally biased region 1, active site 1, modified residue 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5VBB	X-RAY DIFFRACTION	1.94

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UJJ7-F1	86.85	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 67

Post-translational modifications (1): 1

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 74 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_UP, GOBP_RIBOSOME_BIOGENESIS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_PSEUDOURIDINE_SYNTHESIS, GOBP_RNA_MODIFICATION, MODULE_397, GOBP_RRNA_MODIFICATION, GOBP_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS, MARSON_BOUND_BY_E2F4_UNSTIMULATED, NIKOLSKY_BREAST_CANCER_16P13_AMPLICON, GOMF_PSEUDOURIDINE_SYNTHASE_ACTIVITY, GOMF_INTRAMOLECULAR_TRANSFERASE_ACTIVITY, GOMF_ISOMERASE_ACTIVITY, LU_EZH2_TARGETS_UP, BHAT_ESR1_TARGETS_NOT_VIA_AKT1_UP

GO Biological Process (3): enzyme-directed rRNA pseudouridine synthesis (GO:0000455), pseudouridine synthesis (GO:0001522), RNA modification (GO:0009451)

GO Molecular Function (3): RNA binding (GO:0003723), pseudouridine synthase activity (GO:0009982), protein binding (GO:0005515)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
rRNA pseudouridine synthesis	1
RNA modification	1
RNA metabolic process	1
macromolecule modification	1
nucleic acid binding	1
intramolecular transferase activity	1
binding	1

Protein interactions and networks

STRING

1589 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RPUSD1	RPUSD3	Q6P087	795
RPUSD1	PUS7L	Q9H0K6	793
RPUSD1	PUS3	Q9BZE2	766
RPUSD1	PUS10	Q3MIT2	744
RPUSD1	PUS1	Q9Y606	724
RPUSD1	TRUB2	O95900	707
RPUSD1	PUS7	Q96PZ0	663
RPUSD1	TRUB1	Q8WWH5	654
RPUSD1	PUSL1	Q8N0Z8	608
RPUSD1	CHTF18	Q8WVB6	507
RPUSD1	DCTN5	Q9BTE1	488
RPUSD1	DKC1	O60832	469
RPUSD1	NOP10	Q9NPE3	413
RPUSD1	THUMPD2	Q9BTF0	410
RPUSD1	INAFM1	C9JVW0	407

IntAct

10 interactions, top by confidence:

A	B	Type	Score
SPRED1	RPUSD1	psi-mi:“MI:0915”(physical association)	0.560
HNRNPCL2	RPUSD1	psi-mi:“MI:0915”(physical association)	0.400
RPUSD1	FOXJ1	psi-mi:“MI:0915”(physical association)	0.370
Tnks2	AMOTL2	psi-mi:“MI:0914”(association)	0.350
Klhl21	DERL1	psi-mi:“MI:0914”(association)	0.350
Ankfy1	ANXA2	psi-mi:“MI:0914”(association)	0.350
PTEN	DNAAF8	psi-mi:“MI:0914”(association)	0.350

BioGRID (8): RPUSD1 (Affinity Capture-MS), RPUSD1 (Affinity Capture-MS), RPUSD1 (Affinity Capture-MS), RPUSD1 (Affinity Capture-RNA), RPUSD1 (Proximity Label-MS), RPUSD1 (Affinity Capture-MS), RPUSD1 (Affinity Capture-MS), RPUSD1 (Two-hybrid)

ESM2 similar proteins: A2RT67, A2RUS2, A3BN26, A4PCD4, A5PKL6, E9PYK3, F1ND48, O75616, P04053, P06526, P09838, P36195, P42118, Q08C69, Q0DST9, Q149F1, Q14AI6, Q17QT4, Q28C59, Q2TBK7, Q3U269, Q3U3W5, Q49MI3, Q4QQT0, Q4R6Y8, Q5E9Z1, Q5EBA0, Q5M721, Q5M934, Q5RL51, Q61846, Q66KI9, Q6DBR0, Q6P087, Q8BGG7, Q8IZ73, Q8NEC7, Q8TF42, Q8VCZ8, Q92089

Diamond homologs: O16686, O25114, O25441, O25610, O66114, O67638, P0A5T3, P0AA37, P0AA38, P0AA41, P0AA42, P33640, P43930, P44197, P44433, P45614, P47451, P53294, P57430, P59831, P59840, P70870, P74346, P75485, P9WHQ2, P9WHQ3, Q08C69, Q0DST9, Q12069, Q149F1, Q17QT4, Q1RJX7, Q3ECD0, Q45480, Q45826, Q47417, Q4QQT0, Q4UKQ3, Q5M721, Q68XB2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

102 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	89
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

850 predictions. Top by Δscore:

Variant	Effect	Δscore
16:786826:C:CA	donor_gain	1.0000
16:786839:T:TA	donor_gain	1.0000
16:787075:AC:A	donor_gain	1.0000
16:787076:C:CA	donor_gain	1.0000
16:787348:TCTTA:T	donor_loss	1.0000
16:787351:TA:T	donor_loss	1.0000
16:787352:A:AC	donor_gain	1.0000
16:787353:C:CC	donor_gain	1.0000
16:787475:AACC:A	acceptor_loss	1.0000
16:787476:ACC:A	acceptor_loss	1.0000
16:787478:C:CC	acceptor_gain	1.0000
16:787550:CCCTA:C	donor_loss	1.0000
16:787551:CCTAC:C	donor_loss	1.0000
16:787552:CTAC:C	donor_loss	1.0000
16:787553:TACCT:T	donor_loss	1.0000
16:787554:ACCTG:A	donor_loss	1.0000
16:787555:C:G	donor_loss	1.0000
16:787567:G:C	donor_gain	1.0000
16:786373:CCGGC:C	acceptor_gain	0.9900
16:786374:CGGC:C	acceptor_gain	0.9900
16:786374:CGGCC:C	acceptor_gain	0.9900
16:786377:CCT:C	acceptor_loss	0.9900
16:786378:C:CC	acceptor_gain	0.9900
16:786378:CTGCG:C	acceptor_loss	0.9900
16:786379:T:C	acceptor_loss	0.9900
16:786822:CACA:C	donor_loss	0.9900
16:786825:A:AC	donor_gain	0.9900
16:786825:A:T	donor_loss	0.9900
16:786825:AC:A	donor_gain	0.9900
16:786826:C:CC	donor_gain	0.9900

AlphaMissense

2007 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:787460:T:A	D67V	0.999
16:786374:C:G	R172P	0.998
16:787369:C:A	K97N	0.998
16:787369:C:G	K97N	0.998
16:787459:A:C	D67E	0.998
16:787459:A:T	D67E	0.998
16:786369:G:C	H174D	0.997
16:787447:G:C	S71R	0.997
16:787447:G:T	S71R	0.997
16:787449:T:G	S71R	0.997
16:787460:T:C	D67G	0.997
16:787460:T:G	D67A	0.997
16:787669:C:A	K23N	0.997
16:787669:C:G	K23N	0.997
16:786364:C:A	Q175H	0.996
16:786364:C:G	Q175H	0.996
16:786367:G:C	H174Q	0.996
16:786367:G:T	H174Q	0.996
16:786377:C:T	G171D	0.996
16:787471:G:C	C63W	0.996
16:787472:C:T	C63Y	0.996
16:787558:G:C	F60L	0.996
16:787558:G:T	F60L	0.996
16:787559:A:G	F60S	0.996
16:787560:A:G	F60L	0.996
16:786275:C:A	R205I	0.995
16:786275:C:G	R205T	0.995
16:786349:G:C	C180W	0.995
16:786360:G:T	R177S	0.995
16:786841:A:G	L166P	0.995

dbSNP variants (sampled 300 via entrez): RS1000261081 (16:789879 G>A,T), RS1001515157 (16:789743 T>C,G), RS1001808659 (16:785547 C>A), RS1002088427 (16:784826 G>C), RS1002519499 (16:789180 C>A,G,T), RS1003350822 (16:788556 A>G), RS1003490214 (16:787852 G>A,C), RS1003736480 (16:787981 C>G,T), RS1004452143 (16:788853 G>A,C,T), RS1005185971 (16:785314 C>T), RS1005259565 (16:785406 C>A,T), RS1005508792 (16:785134 G>A), RS1005890644 (16:784657 G>A,T), RS1006193334 (16:784715 G>A,C,T), RS1006248045 (16:787866 G>A)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005951_12	Body mass index	5.000000e-11

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression	2
triphenyl phosphate	affects expression	1
abrine	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	decreases expression	1
Temozolomide	increases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cadmium	increases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Selenomethionine	affects expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1
Sodium Selenite	increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer